Also trades as: CING (NASDAQ) · $vol 2M
CINGW NASDAQ
Cingulate Inc.
1W: +24.5%
1M: +29.5%
3M: -55.0%
YTD: -56.8%
1Y: -34.1%
3Y: -88.2%
$0.03
+0.00 (+13.28%)
Weekly Expected Move ±149.6%
$-0
$-0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider+$0.3M
Congress—
ETF Holdings—
Key Statistics
Market Cap$0.2M
52W Range0.0171-0.0385
Volume10,133
Avg Volume39,560
Beta-0.15
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOShane J. Schaffer
Employees13
SectorHealthcare
IndustryBiotechnology
IPO Date2021-12-08
Websitecingulate.com
1901 West 47th Place
Kansas City, KS 66205
US
Kansas City, KS 66205
US
913 942 2300
About Cingulate Inc.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
Latest News
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
Cingulate Inc. (NASDAQ:CINGW) Sees Large Increase in Short Interest
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Silva Raul R. | A-Award | 4,526 | — | 2026-03-09 |
| Silva Raul R. | F-InKind | 1,828 | — | 2026-03-09 |
| Schaffer Shane J. | A-Award | 6,862 | — | 2026-03-09 |
| Schaffer Shane J. | F-InKind | 2,959 | — | 2026-03-09 |
| Callahan Jennifer L. | A-Award | 15,329 | — | 2026-03-09 |